At Exscientia, we are committed to changing the way the world invests impactful medicines by encoding and automating drug discovery and development. We believe that devoting ourselves to current and future clinical trial programmes provides the best path to meet our goal of providing therapeutics to patients with cancer.

Expanded access, or compassionate use, is the use of an investigational medicine prior to regulatory approval and outside of a clinical trial. We understand that for patients with serious diseases such as cancer, waiting for an approved treatment can be difficult. We encourage you to speak with your physician about options that may be right for you.

Exscientia does not currently have an expanded access program or compassionate use program for any of our investigational products.